211 related articles for article (PubMed ID: 15943041)
21. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
22. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
23. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma.
Qiu SJ; Ye SL; Wu ZQ; Tang ZY; Liu YK
J Cancer Res Clin Oncol; 1998; 124(5):253-8. PubMed ID: 9645455
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
25. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
26. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
27. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
28. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
[TBL] [Abstract][Full Text] [Related]
29. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
30. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors.
Iwato M; Tachibana O; Tohma Y; Nitta H; Hayashi Y; Yamashita J
Acta Neuropathol; 2000 Jan; 99(1):21-5. PubMed ID: 10651023
[TBL] [Abstract][Full Text] [Related]
32. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
33. p53 alterations and their relationship to SDHD mutations in parasympathetic paragangliomas.
van Nederveen FH; Dannenberg H; Sleddens HF; de Krijger RR; Dinjens WN
Mod Pathol; 2003 Sep; 16(9):849-56. PubMed ID: 13679447
[TBL] [Abstract][Full Text] [Related]
34. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
35. Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas.
Ohnishi H; Kawamura M; Hanada R; Kaneko Y; Tsunoda Y; Hongo T; Bessho F; Yokomori K; Hayashi Y
Genes Chromosomes Cancer; 1996 Mar; 15(3):187-90. PubMed ID: 8721685
[TBL] [Abstract][Full Text] [Related]
36. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.
Keleti J; Quezado MM; Abaza MM; Raffeld M; Tsokos M
Am J Pathol; 1996 Jul; 149(1):143-51. PubMed ID: 8686737
[TBL] [Abstract][Full Text] [Related]
37. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
Zhang J; Liu H; Li S; Gu C
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371
[TBL] [Abstract][Full Text] [Related]
38. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
39. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
40. Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators.
Schlott T; Scharf JG; Gorzel C; Middel P; Spring H
Br J Cancer; 2002 Apr; 86(8):1290-6. PubMed ID: 11953887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
